Extended Data Fig. 8: iVAC induces tumours to acquire APC-like functions via PD-L1 degradation and OVA antigen presentation.
From: Intratumoural vaccination via checkpoint degradation-coupled antigen presentation
a,b, Representative flow cytometry plots (a) and quantification (b) of OVA (SIINFEKL) tetramer+ CD8+ T cells in PBMCs from mice immunized with OVApep (n = 5 mice per group). c, iVAC treatment induced PD-L1 degradation similar to GlueBody2-CPP and resulted in increased infiltration of CD3+ and CD11c+ cells in tumours. Data are representative of three mice per group. Scale bar: 100 μm. d,e, Representative flow cytometry plots (d) and quantification (e) of tumour PD-L1 levels (n = 3 mice per group). f,g, Representative flow cytometry plots (f) and quantification (g) of OVApep-MHC-I complexes on tumour cells (n = 3 mice per group). Data are the mean ± s.d. Statistics: the unpaired two-sided Student’s t-test (b) and one-way ANOVA (e, g) with Tukey’s multiple comparisons test. NS: not significant.
